Clinical comparison of triphasic norgestimate/35 μg ethinyl estradiol and monophasic norethindrone acetate/20 μg ethinyl estradiol: Cycle control, lipid effects, and user satisfaction
- 31 March 1999
- journal article
- clinical trial
- Published by Elsevier in Contraception
- Vol. 59 (3) , 161-166
- https://doi.org/10.1016/s0010-7824(99)00026-8
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Uniqueness of oral contraceptive progestinsContraception, 1998
- Estrogen and progestin components of oral contraceptives: Relationship to vascular diseaseContraception, 1997
- Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiolActa Obstetricia et Gynecologica Scandinavica, 1992
- Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agentActa Obstetricia et Gynecologica Scandinavica, 1992
- The efficacy and tolerability of norgestimate/ethinyl estradiol (250 μg of norgestimate/35 μg of ethinyl estradiol): Results of an open, multicenter study of 59,701 womenAmerican Journal of Obstetrics and Gynecology, 1992
- A randomized, double-blind study of six combined oral contraceptivesContraception, 1982
- A RANDOMIZED DOUBLE‐BLIND TRIAL OF TWO LOW DOSE COMBINED ORAL CONTRACEPTIVESBJOG: An International Journal of Obstetrics and Gynaecology, 1979